|
|
 Previous Article | Table of Contents | Next Article 
Plasma cells in multiple myeloma express a natural killer cell- associated
antigen: CD56 (NKH-1; Leu-19)
B Van Camp, BG Durie, C Spier, M De Waele, I Van Riet, E Vela, Y Frutiger, L Richter and TM Grogan
Department of Internal Medicine, University of Arizona College of Medicine,
Tucson.
Bone marrow samples from 55 patients with multiple myeloma (MM) and 23
patients with monoclonal gammopathy of undertermined significance (MGUS)
were evaluated with a broad panel of monoclonal antibodies. Plasma cells
from 78% (43/55) of patients with MM strongly expressed the natural killer
cell antigen CD56 (NKH-1, Leu-19). Of the 23 patients with MGUS, none
showed strong CD56 reactivity, although three had weak reactivity in less
than 20% of plasma cells. Myeloma cells expressing CD56 did not coexpress
the CD57 or CD16 antigens. Patients with CD56-positive plasma cells had
both indolent and aggressive disease. However, the 12 CD56-negative
patients had predominantly aggressive disease with an unexpected
preponderance of kappa Bence Jones only myeloma (5/10[50%] evaluable
patients). Polyclonal plasma cells from non-neoplastic tissue sites (normal
bone marrows, lymph nodes, tonsillar biopsies, and gut-mucosa biopsies)
showed a near absence of CD56. We conclude that isolated, strong CD56
expression is common in MM, but not in MGUS or reactive plasma cells. The
potential biologic importance of CD56 positivity in myeloma is reviewed.
Volume 76,
Issue 2,
pp. 377-382,
07/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J Yeung and H Chang
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
J. Clin. Pathol.,
July 1, 2008;
61(7):
832 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Suzuki, M. Suzuki, J. Nakayama, A. Suzuki, K. Angata, S. Chen, K. Sakai, K. Hagihara, Y. Yamaguchi, and M. Fukuda
Polysialic acid facilitates tumor invasion by glioma cells
Glycobiology,
September 1, 2005;
15(9):
887 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kouno, T. Watanabe, T. Umeda, Y. Beppu, R. Kojima, K. Sungwon, Y. Kobayashi, K. Tobinai, T. Hasegawa, and Y. Matsuno
CD56-positive Small Round Cell Tumor: Osseous Plasmacytoma Manifested in Osteolytic Tumors of the Iliac Bone and Femora
Jpn. J. Clin. Oncol.,
February 1, 2005;
35(2):
90 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology,
January 1, 2003;
2003(1):
248 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Ely and D. M. Knowles
Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation
Am. J. Pathol.,
April 1, 2002;
160(4):
1293 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Meech, L. McGavran, L. F. Odom, X. Liang, L. Meltesen, J. Gump, Q. Wei, S. Carlsen, and S. P. Hunger
Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4-anaplastic lymphoma kinase gene fusion
Blood,
August 15, 2001;
98(4):
1209 - 1216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Shin, G. A. Stopyra, M. J. Warhol, and H. A.B. Multhaupt
Plasmacytoma with Aberrant Expression of Myeloid Markers, T-cell Markers, and Cytokeratin
J. Histochem. Cytochem.,
June 1, 2001;
49(6):
791 - 792.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood,
November 1, 2000;
96(9):
2993 - 3000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Sanz, A. Orfao, M. Gonzalez, M.D. Tabernero, J. Blade, M.J. Moro, J. Fernandez-Calvo, M.A. Sanz, J.A. Perez-Simon, A. Rasillo, et al.
Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
Blood,
February 1, 1999;
93(3):
1032 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd
CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?
J. Clin. Oncol.,
January 1, 1999;
17(1):
293 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Q. Lacy, K. A. Donovan, J. K. Heimbach, G. J. Ahmann, and J. A. Lust
Comparison of Interleukin-1beta Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Blood,
January 1, 1999;
93(1):
300 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rambaldi, G. Borleri, G. Dotti, P. Bellavita, R. Amaru, A. Biondi, and T. Barbui
Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation
Blood,
March 15, 1998;
91(6):
2189 - 2196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Stanley, B. F. Liebersbach, W. Liu, D. J. Anhalt, and R. D. Sanderson
Heparan Sulfate-mediated Cell Aggregation
J. Biol. Chem.,
March 10, 1995;
270(10):
5077 - 5083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
